Dr. Preston Steen
Medical Oncologist/Hematologist/Palliative Medicine
Dr. Preston Steen is a specialist in cancers and blood disorders, currently serving as a medical oncologist, hematologist and palliative medicine specialist at Sanford Roger Marris Cancer Center. Dr. Steen also takes patients at Sanford South University Medical Center.
Dr. Steen has collaborated on numerous clinical trials, focusing on developing new therapies and improving the efficacy of current treatments. He has helped research particular biomarkers and proteins on tumors, investigated second- and third-line treatments for different types of cancer and tested new forms of radiation for lung cancer.
Main Specialty: Oncology
Other Interests & Specialties: Hospice and palliative care, general oncology, hematologic oncology, gastrointestinal cancer and genitourinary oncology.
Certifications, Awards & Accolades: American Board of Internal Medicine Certifications in Internal Medicine and Hospice and Palliative Medicine, American Board of Internal Medicine Certification in Medical Oncology and named America’s Top Doctors for Cancer 2010 – 2015.
Education & Experience:
- Medical Degree from University of Minnesota Medical School
- Residency for Internal Medicine at Maricopa Medical Center
- Fellowship for Hematology and Oncology at University of Utah
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncology. December 2016;17(12):1661-1671. doi: 10.1016/S1470-2045(16)30561-7
A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621. Lung Cancer. August 2014;85(2):245-50. doi: 10.1016/j.lungcan.2014.03.004
Pilot study of human recombinant interferon gamma and accelerated hyperfractionated thoracic radiation therapy in patients with unresectable stage IIIA/B nonsmall cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. February 1995;31(4):827-31.